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Abstract
Background: Recent advances in bioinformatics have made it possible to predict the B cell and T cell epitopes of antigenic
proteins. This has led to design of peptide based vaccines that are more specific, safe, and easy to produce. The obligately
intracellular gram negative bacteria Ehrlichia cause ehrlichioses in humans and animals. As yet there are no vaccines to
protect against Ehrlichia infection.
Methodology/Principal Findings: We applied the principle of structural vaccinology to design peptides to the epitopes of
Ehrlichia muris outer membrane P28-19 (OMP-1/P28) and Ehrlichia Heat shock protein 60 (Hsp60/GroEL) antigenic proteins.
Both P28-19 and Ehrlichia Hsp60 peptides reacted with polyclonal antibodies against E. canis and E. chaffeensis and could be
used as a diagnostic tool for ehrlichiosis. In addition, we demonstrated that mice vaccinated with Ehrlichia P28-19 and
Hsp60 peptides and later challenged with E. muris were protected against the pathogen.
Conclusions/Significance: Our results demonstrate the power of structural vaccines and could be a new strategy in the
development of vaccines to provide protection against pathogenic microorganisms.
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Introduction
Vaccines are considered as one of the most successful medical
intervention against infectious diseases. Vaccines include killed or
attenuated organisms or purified products derived from them.
One of the drawbacks of killed or attenuated vaccines is the
potential side effect of some of the antigenic proteins. This led to
the design of recombinant vaccines based on whole antigens. As
whole antigenic proteins are not essential in inducing immunity, it
led to the emergence of a new branch of vaccine design termed
structural vaccinology [1,2]. Structure based vaccines have the
rationale that protective epitopes are enough to induce immune
responses and provide protection against pathogens [3]. Structure-
based peptide antigens induce antibodies which recognize the
denatured form of a protein from which their sequences are
derived [4].
The obligate intracellular bacterium Ehrlichia chaffeensis that
resides in mononuclear phagocytes is the etiologic agent of human
monocytotropic ehrlichiosis (HME). HME is an emerging and
often life-threatening zoonotic, tick-transmitted infectious disease
in the United States [5–7]. Lack of early diagnosis and treatment
of HME are the main factors that lead to severe and fatal disease.
Ehrlichia also causes diseases in companion animals and domes-
ticated ruminants. E. chaffeensis and E. canis cause canine
ehrlichioses in dogs, whereas E. ruminantium causes heartwater in
cattle, sheep and goats. Vaccines are needed for these tick
transmitted pathogens, but are hindered by many obstacles that
exist in their development. These include knowledge of genetic
and antigenic variability, identification of the ehrlichial antigens
that stimulate protective immunity or elicit immunopathology,
development of animal models that reflect the immune responses
of the hosts and understanding molecular host-pathogen interac-
tions involved in immune evasion or that may be blocked by the
host immune response. As yet there are no commercially available
vaccines to protect against ehrlichiosis [8].
Development of a murine model of persistent ehrlichiosis has
greatly facilitated our understanding of the pathogenesis and
mechanisms of host defenses against ehrlichial infections. Mildly
virulent Ehrlichia muris infection in immunocompetent C57BL/6
mice results in persistent infection and mimics E. chaffeensis
infection in its natural host, white-tailed deer [9]. Murine models
of systemic infection associated with the mildly virulent E. muris or
the highly virulent IOE (Ixodes ovatus Ehrlichia) have provided
knowledge of immunological mechanisms involved in host
defenses against ehrlichial infection [9–15]. Protective immunity
against E. muris in the mouse models of ehrlichiosis correlates with
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27981induction of strong cell-mediated CD4 and CD8 type 1 responses
and humoral immunity [12]. T cell independent humoral
immunity has also been reported to be sufficient for protection
against fatal infection with intracellular ehrlichial pathogens [16].
We recently demonstrated that Ehrlichia Hsp60 (GroEL) and
P28 (OMP-1) are the major antigenic proteins of E. muris and they
are also post-translationally modified [17]. Based on these
observations, we bioinformatically identified the predicted hydro-
philic epitope sequences of Ehrlichia Hsp60 and P28-19 and
synthesized peptides to use as diagnostic probes to detect
antibodies against Ehrlichia. In this paper we demonstrate that
both Ehrlichia muris Hsp60 and P28 peptides reacted with
antibodies against E. chaffeensis and E. canis and could be used in
diagnosis of infected animals. We also demonstrated that the
structure-based peptides provided protection against Ehrlichia and
hence could be used as a vaccine against ehrlichioses.
Results
Peptides based on the epitopes of Ehrlichia Hsp60 and
outer membrane protein P28-19 detected pathogen-
specific antibodies
The outer membrane proteins P28 and Ehrlichia Hsp60 (GroEL)
are the major antigenic proteins of Ehrlichia [17]. Previous studies
in our laboratory and elsewhere have demonstrated that P28-19 is
the most efficient and protective P28 paralog which provides
protection against Ehrlichia [18,19].
We identified the Ehrlichia Hsp60 and P28-19 epitopes based on
the predicted hydrophilicity [20]. Three regions of the E. muris
P28-19 protein sequence had substantial predicted hydrophilicity
as determined by the Lasergene software. The peptides correspond
to amino acids 55–75, 91–103, and 124–145 (Fig. 1). Initial studies
demonstrated that the peptide corresponding to the amino acids
55–75 of the P28-19 protein is more sensitive in detection of
Ehrlichia specific antibodies. Based on the information we injected
P28-19 55275 peptide to induce antibody generation or function as
a vaccine candidate.
Three regions of the Ehrlichia Hsp60 protein sequence had
substantial predicted hydrophilicity as determined by the Laser-
gene software (DNAStar, WI, USA). The peptides correspond to
amino acids 43–63, 179–200, and 386–406 (Fig. 2). The peptide
corresponding to amino acid 43–63 of Ehrlichia Hsp60 was found
to be more reactive with various Ehrlichia- specific antibodies and
also induced production of antibodies (Fig. 2). Based on the
information we injected Ehrlichia Hsp60 43–63 peptide to induce
antibody generation or function as a vaccine candidate.
We probed for Ehrlichia-specific antibodies in sera of mice
infected with E. muris. As a control we used recombinant P28-19
protein. The peptide P28-19 55–75 was found to be more sensitive
in detecting Ehrlichia-specific antibody than recombinant P28-19.
The peptide detected the Ehrlichia-specific antibody even from sera
of mice obtained as early as seven days after E. muris infection
(Fig. 3). In subsequent studies we used P28-19 55-75 as a diagnostic
probe or vaccine candidate.
Figure 1. Amino acid sequence of P28-19. (A)P28-19 peptidescorresponding tothe underlinedpredicted hydrophilic sequencewere synthesized.
The peptide corresponding to the bold underlined (55–75) sequence was found to react with antibodies to Ehrlichia as well as to induce antibody
production. (B) Hydrophobicity plot of P28-19. The sequences underlined (in red and blue) were used for synthesizing peptides; however the best
peptide sequence selected is underlined in red. (C) (Left) Predicted 3D structure of P28-19 (side view), (Middle) predicted 3D structure of P28-19 (basal
view), (Right) predicted 3D structure of P28-19 with the Van der Waals radii of the heavy atoms highlighting the region of interest (P28-19 55275).
doi:10.1371/journal.pone.0027981.g001
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efficacy of both P28-19 55–75 and Hsp60 43–63 peptides as
diagnostic tools. We coated the peptides on an ELISA plate and
assayed for E. chaffeensis and E. canis antibody from sera of infected
dogs. The ELISA plate coated with the Hsp60 43–63 peptide
detected Ehrlichia-specific antibody in the sera of dogs infected with
E. canis or E. chaffeensis (Fig. 4A). The assay confirmed that the
peptide corresponding to the Ehrlichia Hsp60 43–63 epitope could
be used in diagnostics. Similarly, P28-19 55–75 peptide detected
antibodies to both E. chaffeensis and E. canis from infected dog
serum samples, whereas, there was no antibody binding from sera
of uninfected dogs (Fig. 4B). To confirm that P28 and Ehrlichia
Hsp60 peptides are specific to detect Ehrlichia but not other
pathogens we probed sera of mice infected with Rickettsia australis,
R. conorii, R. akari and Orientia tsusugamushi. The P28-19 55-75 and
Ehrlichia Hsp60 43–63 peptides did not react with sera of mice
infected with Rickettsia australis, R. conorii, R. akari and Orientia
tsusugamushi (Fig. 4C, 4D). The experiments demonstrated that
both Ehrlichia Hsp60 43–63 and P28-19 55–75 epitope peptides could
be used as antigens in diagnostic applications.
Antibodies against the epitopes of Ehrlichia Hsp60 and
the outer membrane protein P28-19 detected pathogen-
specific antigen
Antibodies are used extensively as diagnostic tools in a wide
array of different analyses. We injected different amounts of
Ehrlichia Hsp60 43–63 to induce polyclonal antibody. Fifty
micrograms (0.02 mM) of Ehrlichia Hsp60 43–63 peptide induced
the optimum amount of antibody for our studies (data not shown).
Using ELISA we determined the detectable level of antibody
which could bind to Ehrlichia Hsp60 43–63 peptide. The antibody to
Ehrlichia Hsp60 detected Ehrlichia Hsp60 43–63 peptide even at a
Figure 2. Amino acid sequence of Ehrlichia Hsp60. (A) Hsp60 peptides corresponding to the underlined predicted hydrophilic sequence were
synthesized. The peptide corresponding to the bold underlined (43–63) sequence was found to react with antibodies to Ehrlichia as well as to induce
antibody production. (B) Hydrophobicity plot of Ehrlichia Hsp60. The sequences underlined (in red and blue) were used for synthesizing peptides;
however, the best peptide sequence selected is underlined in red. (C) (Left) Predicted 3D structure of Ehrlichia Hsp60, (Right) predicted 3D structure
of Ehrlichia Hsp60 with the Van der Waals radii of the heavy atoms highlighting the region of interest (Hsp60 43–63).
doi:10.1371/journal.pone.0027981.g002
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ANOVA). We also used the antibody to probe for E. muris and
E. chaffeensis in DH82 monocytic cells [21]. To determine whether
the antibodies against the epitope of P28-19 55–75 could be used as
a probe we immunized mice with P28-19 55–75 peptide and used
theseraasa probetodetectE.murisinDH82cells.TheP28-19 55–75
peptide induced antibody production that detected E. muris in
DH82 cells as determined by fluorescence microscopy (Fig. 6A).
The peptides of P28-19 55–75 and Ehrlichia Hsp60 43–63
functioned as vaccines to protect against the pathogen
Since the P28-19 55–75 and Ehrlichia Hsp60 43–63 epitope
peptides induced antibodies, we reasoned that they also could
provide protection against Ehrlichia thereby functioning as
potential vaccine candidates. To prove our hypothesis mice were
injected with P28-19 55–75 or Ehrlichia Hsp60 43–63 epitope peptides
and challenged 30 days later with E. muris. The spleen and liver
were collected at different days after bacterial challenge and the
bacterial copy number determined by quantitative real time PCR.
We observed lower bacterial load in both spleen and liver on days
7 and 14 after bacterial infection in the vaccinated mice compared
to unvaccinated controls (Fig. 7). The results demonstrated that
P28-19 55–75 and Ehrlichia Hsp60 43–63 peptides functioned as
vaccine candidates and provided protection against Ehrlichia
infection.
Immunization with vaccines stimulates the immune system to
produce a robust antibody response that can provide protection
against pathogens. To determine the antibody responses against
the Ehrlichia Hsp60 43–63 peptide vaccine, we collected blood from
vaccinated mice on days 7 and 14 and performed ELISA. There
was a significant difference in the antibody response between
unvaccinated and Ehrlichia Hsp60 43–63 vaccinated mice after
challenge with E. muris. However, there was no difference between
the antibody levels in vaccinated mice between days 7 and 14. The
Ehrlichia Hsp60 43–63-specific antibody levels in infected unvacci-
nated mice were highest on day 14 compared to day 7 (Fig. 8A).
To determine the antibody responses against the P28-19 55–75
peptide vaccine, we collected blood from immunized mice on days
7 and 14 and subjected the samples to ELISA. There was a
significant difference in the antibody response between unvacci-
nated and P28-19 55–75 vaccinated mice after challenge with E.
muris. Antibody levels were higher on day 14 compared to day 7
(Fig. 8B).
As antibody isotype responses can be useful indicators of
immune bias during infection [22], we determined the antibody
isotypes after vaccination with the peptide epitopes. The level of
antibody isotypes increased by day 14 compared to day 7 after
bacterial challenge (data not shown). The Ehrlichia Hsp60 43–63-
vaccinated mice had higher levels of IgG1, IgG2c, IgG2b, IgG3
and IgM after bacterial challenge compared to unvaccinated mice
on day 14 (Fig. 9A). By ELISA we analyzed the isotypes of the
antibodies of P28-19 peptide in vaccinated and unvaccinated mice
after challenge with E. muris (day 14 post challenge). The P28-19 55–75
vaccinated mice challenged with E. muris had higher levels of IgG1,
IgG2b, IgG3 and IgM compared to unvaccinated mice infected with
the pathogen (Fig. 9B).
Ehrlichia Hsp60 and P28-19 specific memory CD4+ Th1
responses are induced during E. muris infection
We determined by flow cytometry if Ehrlichia Hsp60 43–63 and
P28-19 specific memory T cells are induced during E. muris
infection. Splenocytes from E. muris-infected mice were harvested
on day 45 post-infection and stimulated in vitro with the Ehrlichia
Hsp60 43–63 and P28-19 55–75 for 18h. Compared to uninfected
naı ¨ve mice, E. muris-infected mice had significantly higher
frequencies and absolute numbers of Ehrlichia Hsp60 43–63 and
P28-19 55–75 specific IFN-c-producing CD4+ Th1 cells in their
spleen (Figure 10).
Discussion
The genetic diversity of microorganisms presents a challenge in
developing broadly effective vaccines [23]. Vaccine design is
progressing from empiricism towards the increasingly rational
presentation of the targets of protective immunity [1]. Using
structural information of proteins, it is possible to engineer
optimized antigens that are more stable, homogeneous, and
efficiently produced, making immunization more practical and
affordable [1]. Thus structural vaccinology is an emerging strategy
for the rational design of vaccine candidates [2]. Structural
vaccines based on epitopes are more specific, safe, and easier to
produce [24], and peptide vaccines based on the epitopes
represent a potential strategy for the prevention and treatment
of pathogenic diseases, cancers and autoimmune disorders. Their
low cost, ease of synthesis and inherent safety are all attractive
features [25]. Structure-based design has been employed to
develop vaccines against Group B Streptococcus infections [2],
Neisseria [25], and influenza virus [26,27]. Scarselli et al. [28]
combined atomic level structural information with genomics and
classical vaccinology to design a single immunogen that elicits
protective immunity against more than 300 natural variants of the
bacterial pathogen meningococcus group B. This accomplishment
provides a glimpse of the power of structure-based vaccine design
to create immunogens capable of eliciting protective responses
against genetically diverse pathogens.
Ehrlichia are host defense-evasive and cell function-manipulative,
vector-transmitted pathogens and are responsible for serious
diseases of agricultural, veterinary and human importance [8].
E. chaffeensis, E. ewingii, and an E. muris-like organism are the known
species of Ehrlichia infecting humans [5,29,30]. Interestingly, recent
studies demonstrated E. muris-like organisms infecting deer in
Wisconsin [31]. In dogs, E. canis, E. chaffeensis and E. ewingii are the
major pathogens; whereas in livestock of sub-Saharan Africa E.
ruminantium cause serious disease. As yet there are no commercially
available vaccines to protect against ehrlichioses.
Figure 3. P28-19 55-75 peptide reacted with E. muris antibody.
The peptide corresponding to the predicted hydrophilic sequence of
amino acids 55–75 of P28-19 reacted with Ehrlichia antibody. The
peptide was found to be more sensitive in reacting with the Ehrlichia
antibody than the recombinant P28-19 protein (***p,0.001 as
determined by Student t test).
doi:10.1371/journal.pone.0027981.g003
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ruminantium indicate that vaccine-induced immunity is feasible for
Ehrlichia spp. containing defined immunoprotective proteins. Some
ehrlichial proteins targeted by the host immune response are well
defined, such as major OMPs (MAP1, MAP2 and OMP-1) [8].
Studies from our laboratory and othershave previouslydemonstrated
the importance of antibodies in protection against Ehrlichia. Passive
transfer of polyclonal immune sera or mAbs confers protection in
SCID mice against E. muris and E. chaffeensis, respectively [18,32].
Prior studies in mouse models have demonstrated that vaccination
with P28 leads to immunity and clearance of Ehrlichia infection.
Using in silico techniques, we identified the predicted hydrophilic
epitopes of P28-19 and Ehrlichia Hsp60 which induce an antibody
response. We selected epitope regions which did not have any
hydrophobic sequences. Of the three epitopes selected from each
of the two antigenic proteins only the peptide corresponding to
epitope at the N-terminal sequence of the protein was found to be
highly reactive with the sera. One of the reasons the N-terminus
sequence of proteins exhibits immunogenicity is that these regions
have a higher tendency to be exposed in the protein’s native
conformation [33]. We also confirmed by BLAST analysis (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) that the sequences of P28-19 and
Figure 4. Ehrlichia Hsp60 43–63 and P28-19 55–75 peptides reacted with Ehrlichia-specific antibody from dogs infected with E. canis and
E. chaffeensis. (A) Ehrlichia Hsp60 43–63 peptide reacted with antibodies from five dogs infected with E. chaffeensis and five dogs infected with E.
canis. (B) P28-19 55–75 peptide reacted with antibodies from five dogs infected with E. chaffeensis and five dogs infected with E. canis. Each bar
represents the mean of three replicates. The horizontal line in the graphs represents Mean + 3 SD of negative samples. The positive samples are
significantly different from negative samples. (C) P28-19 55–75 peptide did not react with antibodies from mice infected with Rickettsia or Orientia. (D)
Ehrlichia Hsp60 43–63 peptide did not react with antibodies from mice infected with Rickettsia or Orientia.
doi:10.1371/journal.pone.0027981.g004
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conserved in the genus Ehrlichia (data not shown).
Zhang et al. [34] used recombinant proteins and peptides
corresponding to the hypervariable region of P28 to detect
Ehrlichia specific antibody in infected dogs. In our studies we
designed peptides based on hydrophilicity. The P28-19 peptide
corresponding to the amino acid sequence 55–75 had the highest
reactivity with Ehrlichia antibodies, and it also induced antibodies.
A previous study showed that mice immunized with the
recombinant E. chaffeensis P28-19 (rP28) enhanced the spontaneous
clearance of the infection in BALB/c mice [35]. A study by Li et
al. [18] indicated that a mAb directed against the E. chaffeensis P28-
19 (OMP-1g) reduced the bacterial burden in SCID mice. Though
they reported that the region spanning amino acids 68–90 of P28-
19 of E. chaffeensis contains a B cell eptiope, subsequent studies by
the group [19] utilized the 77–92 amino acid sequence to generate
peptides. The peptides were found to be weak in inducing
immunogenicity compared to peptides from other regions of P28-
19. The high specificity of our peptide may be related to the
hydrophilicity of the sequence.
Ehrlichia lacks many genes involved in metabolism, and it
requires various nutrients and metabolic compounds facilitated
through pores or channels in the bacterial outer membrane [36].
Kumagai et al. [36] demonstrated that the Ehrlichia outer
membrane P28-19 has porin activities and the structure of the
protein was consistent with a beta-barrel structure, but the authors
did not show the 3D structure of P28. We confirm based on the
predicted 3D structure that the P28-19 has a beta-barrel structure
and the hydrophilic epitope of our interest is located in the the
external loop. Bioinformatics analyses demonstrated that Ehrlichia
Hsp60 43–63 and P28-19 55–75 are highly conserved in Ehrlichia
(.95%). The peptide corresponding to Ehrlichia Hsp60 amino acid
sequence 43–64 cross reacted with E. canis and E. chaffeensis
antibodies. As the peptides induce an antibody response, we
reasoned that the peptide could function as an immunogen, and
the induced antibodies could clear the pathogens. Our studies
demonstrated that both Ehrlichia Hsp60 43–63 and P28-19 55–75
detected Ehrlichia specific antibodies in mice and dogs infected with
different Ehrlichia species, whereas, the peptides did not react with
any non-specific antibodies. A preliminary experiment demon-
strated that the peptides could also detect Ehrlichia antibodies from
human sera infected with Ehrlichia (data not shown). The results
demonstrated that both the peptides could be used in diagnosis of
Ehrlichia in animals and humans.
As peptides per se are poor in inducing immunogenicity KLH is
used as a career protein. It has been demonstrated that use of
peptides in ELISA in the absence of KLH career protein was
found to be less sensitive [37]. Roberts et al. [37] also demon-
strated that KLH was also necessary for a strong and specific
antibody response. Vaccination with the Ehrlichia Hsp60 43–63 and
P28-19 55–75 peptides did not fully reduce the bacterial load after 7
days of Ehrlichia challenge. By day 14 after bacterial challenge
Figure 5. Reactivity of Ehrlichia Hsp60 antibody. The Ehrlichia
Hsp60 43–63 peptide was sensitive in detecting different dilutions of the
Ehrlichia Hsp60 antibody. The Ehrlichia Hsp60 (250ng) was probed with
different dilutions of Ehrlichia Hsp60 specific sera or sera from naı ¨ve
mice. Finally they were probed with goat anti-mouse-AP (1:2000) and
the OD measured at 650 nm after the addition of substrate. Each value
is the mean of 3 replicates (***p,0.001 as determined by two way
ANOVA).
doi:10.1371/journal.pone.0027981.g005
Figure 6. Detection of E. muris by fluorescence microscopy. (A) Antibodies produced against peptide P28-19 55–75 detected E. muris in infected
DH82 cells. Left: Infected DH82 cell probed with P28-19 antibody, followed by FITC conjugated goat anti-mouse antibody. Middle: DAPI staining.
Right: Merge. Arrows indicate E. muris. (B) Naı ¨ve serum did not detect E. muris in DH82 cells. Left: Infected DH82 cell probed with naive serum,
followed by FITC-conjugated goat anti-mouse antibody. Middle: DAPI staining. Right: Merge. Arrows indicate E. muris.
doi:10.1371/journal.pone.0027981.g006
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increased by day 14 compared to day 7. The low reduction in
bacterial load by day 14 may be due to the high levels of antibody
and its isotypes on day 14 after bacterial challenge.
Hsps are highly conserved in nature from bacteria to humans
[38]. They are molecular chaperones essential for maintaining
cellular functions by preventing misfolding and aggregation of
nascent polypeptides and by facilitating protein folding [39].
Bacterial Hsp proteins are immunomodulatory and are known to
stimulate monocytes and macrophages [40]. Furthermore, Hsps
have been reported to be dominant antigens for the host immune
response to various pathogens and, thus, have great potential as
vaccine candidates [41]. Hsp60 has been an effective subunit
vaccine against Yersinia enterocolitica [42], and Woo et al. [43]
demonstrated that Hsp60 is a highly antigenic protein in
Burkholderia pseudomallei. Patients infected with B. pseudomallei
develop a strong antibody response against Hsp60, suggesting
that the recombinant protein may be useful for serodiagnosis and
vaccine development [43]. Hsp60 of Francisella tularensis was
evaluated as a vaccine candidate by Noah et al. [44], which
elicited secretion of the chemokines CXCL8 and CCL2 through a
TLR4-dependent mechanism. A combination of LPS and Hsp60
increased immunity against the pathogen compared to immuni-
zation with LPS alone. Analysis of antibody isotypes of mice
vaccinated with GroEL of Salmonella enterica serovar Typhi
suggested predominance of the Th2 type immune response in
animals immunized with GroEL and adjuvant, whereas immuni-
zation of animals with GroEL-alone shifted the immune response
Figure 7. Immunization with Ehrlichia Hsp60 43–63 and P28-19 55–75 peptides protected mice from Ehrlichia infection. (A) Mice
immunized with Ehrlichia Hsp60 43–63 were protected against E. muris challenge as determined by the bacterial load measured by quantitative real
time-PCR on day 14 after E. muris challenge (*p,0.05 as determined by t test). (B) Mice immunized with P28-19 55–75 peptide was protected against E.
muris challenge as determined by the bacterial load measured by quantitative real time-PCR on days 7 and 14 after E. muris challenge (**p,0.01 as
determined by t test).
doi:10.1371/journal.pone.0027981.g007
Figure 8. Protection induced by Ehrlichia Hsp60 43–63 and P28-19 55–75 peptides was associated with induction of Ehrlichia- specific
IgG antibody. (A) Ehrlichia Hsp60 43–63 vaccinated mice induced higher IgG antibody levels after challenge with E. muris compared to unvaccinated
E. muris-infected mice (***p,0.001 as determined by t test). (B) P28-19 55–75 peptide vaccinated mice induced higher IgG antibody levels after E. muris
challenge compared to unvaccinated E. muris-infected mice (***p,0.001 as determined by Student t test).
doi:10.1371/journal.pone.0027981.g008
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a significant increase in lymphocyte proliferation and had higher
IFN-c and IL-2 levels [40], and demonstrated effective protection
by Hsp60 against human typhoid. Hsp60 also provided protection
against B. anthracis by stimulating both humoral and cell mediated
immunity [45].
In addition to their use as indicators of cytokine bias during
infection, antibody isotypes have direct functional relevance to
disease severity in helminth-malaria co-infection. Antibodies are
absolutely required for the ultimate clearance of malaria parasites.
In mice, antibodies of the cytophilic isotype IgG2a have been
shown to recognize infected erythrocytes and facilitate their
destruction by phagocytes. Similarly, in humans IgG1 and IgG3
antibodies are associated with enhanced parasite clearance
(reviewed by Fairlie-Clarke et al. [22]).
We observed an increase in spleen size (splenomegaly) after
infection (data not shown). The size of the spleen was largest on
day 14 and was gradually reduced after day 21, and by day 28 the
size corresponded to that of a normal mouse. E. muris infection
resulted in an increase in antibody levels on day 14 after bacterial
infection; interestingly the vaccinated mice also cleared the
bacteria completely on day 14. It has been demonstrated that
antibodies against Bordetella parapertussis have no effect until B.
parapertussis-specific T cell responses are generated around day 14
[46]. The Ehrlichia Hsp60 and P28-19 peptides are likely to induce
CD4+ T cell responses as we detected antigen-specific IFN-c-
producing memory CD4+ T cells in mice infected with E. muris on
day 45 post-infection. Our study suggests Ehrlichia Hsp60 43–63 and
P28-19 55–75 peptides controlled Ehrlichia by stimulating B and T
cells.
Overall, our studies demonstrate the power of structural
vaccinology. Peptides designed based on the hydrophilicity of
P28-19 and Ehrlichia Hsp60 could act as diagnostic antigens and
could also function as a vaccine. Rudra et al. [47] demonstrated a
self-assembling peptide acting as an immune adjuvant. Future
studies will involve the design and development of structural
vaccines, which could also include peptide sequences that could
act as adjuvants.
Materials and Methods
Design of P28-19 and Ehrlichia Hsp60 peptides
To determine a protein sequence for potential antigenic
epitopes, sequences that are hydrophilic, surface-oriented, and
flexible are selected. Most naturally occurring proteins in aqueous
solutions have their hydrophilic residues on the protein surface
and hydrophobic residues buried in the interior. Three regions of
the E. muris P28-19 and Hsp60 protein sequence had good
hydrophilicity predicted by the Lasergene software (DNAStar,
WI, USA). We selected hydrophilic sequences of both the
Ehrlichia P28-19 and Hsp60 proteins with no hydrophobic
residues. The hydrophilic regions of P28-19 correspond to amino
acids 55–75, 91–103, and 124–145 (Fig. 1). The hydrophilic
regions of Ehrlichia Hsp60 correspond to amino acids 43–63, 179–
199, and 387–406 (Fig. 2). The sequences showed homology to
other Ehrlichia species. The peptides (underlined) were synthesized
and conjugated to KLH (Biosynthesis, Lewisville, TX) and used
as probes to detect antibodies to E. canis and E. chaffeensis or to
raise antibodies.
3D structure prediction
The 3D structure of P28-19 in Fig. 1 was modeled using the
online I-TASSER (iterative threading assembly refinement)
server [48,49]. I-TASSER builds 3D models from an amino
acid sequence using fold recognition and multiple-threading
alignments by LOMETS, a meta-threading server in the Zhang
lab at the Univ. of Michigan which combines seven state-of-the-
art threading programs (FUGUE, HHsearch, MUSTER,
PROSPECT, PPA, SP3 and SPARK) then performs iterative
structural assembly simulations. The function of the predicted
models is then inferred by structurally matching the 3D models
with known proteins using protein function databases. The best
predicted model from I-TASSER (Fig. 1) gave a C-score of
23.338, a TM-score of 0.3460.12, and an Exp. RMSD of
14.163.8. The C-score is a confidence value for estimating the
quality of the model and generally ranges from [25, 2] with a
higher score being better; TM-scores measure structural
similarity and are used to measure the accuracy of structural
modeling with a TM-score .0.5 indicating a model having the
correct topology and a TM-score ,0.17 showing random
similarity. RMSD is simply the average distance of all amino
acid pairs between two structures. Protein segments that are
relatively unstructured such a loops and coils can result in high
RMSD scores. Based on these results the beta-barrel portion of
the model in Fig. 1 is likely to be a reasonable representation of
the 3D structure of body of the protein. The coils however,
which were modeled ab initio, are likely idiosyncratic and there is
no way to verify their structure without doing x-ray crystallog-
raphy or NMR, which are well-beyond the scope of this study.
We double checked this model against the best model produced
by Phyre2 with similar results. Thus, this model should be
approached with caution and care taken not to over-interpret the
structure of the loops and coils.
Figure 9. Antibody isotypes in mice immunized with Ehrlichia Hsp60 43–63 and P28-19 55–75 peptides. (A) Mice vaccinated with Ehrlichia
Hsp60 43–63 peptide had higher levels of IgG1, IgG2c, IgG2b, and IgG3 compared to unvaccinated mice after bacterial challenge. (B) Mice vaccinated
with P28-19 55–75 peptide had higher levels of IgG1, IgG2b, IgG2c, and IgG3 compared to unvaccinated mice after bacterial challenge. The data were
expressed as mean plus standard deviation and three mice per group were included for analysis.
doi:10.1371/journal.pone.0027981.g009
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using the online Phyre2 server [50]. Phyre2 aligns hidden
Markov models via HHsearch to improve alignment accuracy
and detection rate. In ‘‘intensive’’ mode, which was used here,
Phyre2 also incorporates Poing [51], a new ab initio folding
simulation based on Langevin dynamics, to model regions of the
protein that have no detectable homology with known structures.
For our Hsp60 sequence, 100% of the residues were modeled at
.90% confidence level. The top three PDB models, all GroEL
chaperone proteins, had 100% confidence levels and sequence ids
of 51–56%. While the model presented in Fig. 2 is likely to be a
reasonable estimate of the true 3D structure of this protein, there
is no way to validate this so caution should be used in its
interpretation.
Detection of anti-Ehrlichia antibodies using the Ehrlichia
Hsp60 43–63 and P28-19 55–75 peptides
We used ELISA to detect Ehrlichia antibodies in the sera of
infected mice and dogs. 250 nanograms of the peptides were
coated on an ELISA plate (MaxiSorp, Nunc, Denmark) for 1 hour
at room temperature. After washing, the plates were blocked with
5% FCS (in PBS-Tween) for 1 hour. The plates were further
incubated with sera of infected mice or dogs for 1 hour at room
temperature. Washing was followed by incubation with secondary
Figure 10. Ehrlichia Hsp60 43–63 and P28-19 55–75 -specific memory CD4+ T cells develop during E. muris infection. We determined by
flow cytometry the frequencies and absolute numbers of Ehrlichia Hsp60 43-63- and P28-19–specific IFN-c-producing CD4+ T cells in the spleen of
mice infected with E. muris. (A) Mice infected with E. muris had higher frequency of Ehrlichia Hsp60 43–63- and P28-19 55–75 -specific IFN-c-producing
CD4+ T cells in the spleen on day 45 after infection compared to naı ¨ve uninfected mice. Representative dot plots were gated on live cells followed by
CD3+ T cells (B) Absolute numbers of E. muris-specific IFN-c-producing CD4+ T cells in the spleen of the same mice detected following in vitro
stimulation with the Ehrlichia Hsp60 43–63, P28-19 55–75 peptides; rP28-19 and E. muris whole cell lysate are shown for comparison. Horizontal bars
represent the mean; data are representative of two independent experiments (n =3 animals per group).
doi:10.1371/journal.pone.0027981.g010
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Perry Laboratories, Gaithersburg, MD) for 1 hour. After the
addition of substrates (Blue Phos
TM phosphatase substrate,
Kirkegaard and Perry Laboratories, Gaithersburg, MD), optical
densities were measured using an ELISA plate reader (Molecular
Devices, Sunnyvale, CA) at 650 nm after 30 min. incubation at
room temperature. All assays were performed in triplicate wells,
and the average values were calculated.
Mice
Six to eight-week old female C57BL/6 mice were used in all
experiments. Mice were purchased from the Jackson Laboratory
(Bar Harbor, ME) and housed and cared for in the Animal
Research Center at the University of Texas Medical Branch in
accordance with the Institutional Animal Care and Use Commit-
tee guidelines under whose review and approval the experiments
were conducted (Protocol No. 95-09-066).
Immunizations and Ehrlichia muris challenge
Mice were immunized i.p., with two doses of 50 micrograms
(0.02 mM) of each P28-19 55–75 peptide or Ehrlichia Hsp60 43–63
peptides conjugated to KLH 15 days apart (the first immunization
with complete Freund’s adjuvant and the second immunization
with incomplete Freund’s adjuvant) (3 mice per group). Thirty
days after the first immunization mice were challenged intraper-
itoneally (i.p.) with a high dose of E. muris (,1610
4 bacterial
genomes) and observed daily. Controls included unchallenged
naı ¨ve mice as well as unvaccinated mice injected with E. muris
alone. Mice were sacrificed on days 7, 14 and 21 after ehrlichial
challenge, and spleen and liver were harvested and sera collected.
The ehrlichial load in spleen and liver was determined by
quantitative RT-PCR. Sera were assayed for determination of
antibody titers.
Measurement of antibody subclasses
ELISA was performed to measure the concentration of E. muris-
specific IgG subclass antibodies as described previously [13,52].
Briefly, the ELISA plates were coated with 50 ml of peptide
(Ehrlichia Hsp60 43–63) or recombinant P28-19 protein at a
concentration of 4 mg/ml in PBS. Serum samples were diluted
1:100, and 100 ml of each sample was added to peptide-coated
wells and incubated at 25uC for 1 h. Alkaline phosphatase-
conjugated goat anti-mouse IgG1, IgG2c, IgG2b, IgG3, or IgM
antibodies (SouthernBiotech, Birmingham, AL) were added at a
dilution of 1:300, and color was developed using Blue Phos
TM
phosphatase substrate (Kirkegaard and Perry Laboratories,
Gaithersburg, MD). Optical densities were measured using an
ELISA plate reader (Molecular Devices, Sunnyvale, CA) at
650 nm after 30 min. incubation at room temperature. All assays
were performed in triplicate wells, and the average values were
calculated. When peptides conjugated to KLH were used as a
probe in ELISA, KLH was used as control and the results
subtracted from positive values.
Fluorescence microscopy
P28-19 55–75 peptides were injected (i.p. - two times, 15 days
apart) into C57BL/6 mice. Antibody was obtained 40 days
after the first injection. E. muris infected DH82 cells were fixed
in 50% methanol-acetone for 5 minutes and later incubated
with the anti-Ehrlichia P28-19 55–75 antibody (or naı ¨ve antibody
as control) (1:125) (45 min). After three washes in PBS they
were reacted with anti-mouse immunoglobulin G conjugated to
Alexa 488. Finally they were mounted in mounting medium
containing DAPI (Vectashield, Vector Labs, Burlingame,
CA). Experiments were repeated three times. The cells
were viewed by epifluorescence microscopy (Olympus BX51,
Japan).
Assessment of ehrlichial load in organs by quantitative
real-time PCR
The bacterial burdens in the organs were determined by
quantitative real-time PCR. Ehrlichia-specific dsb gene, which
encodes a disulfide bond-forming protein (GenBank accession #
AY236484 and AY236485) was selected as the target gene for
amplification of E. muris. The sequences of the primers and probes
and thermal cycle conditions were described previously [15]. PCR
analyses were considered negative for ehrlichial DNA if the critical
threshold values (Ct) exceeded 40 cycles. Expression of the
ehrlichial load was normalized relative to the total DNA (Figure 6).
Each sample was run in duplicate.
Assessment of Hsp60- and P28-19-specific memory CD4+
T cell responses in E. muris-infected mice
The frequencies of antigen specific IFN-c-producing T cells in
the spleens were determined by flow cytometric analysis.
Splenocytes of individual mice were cultured in vitro in a 12-well
plate at a concentration of 5610
6 cells per well in complete
medium (RPMI 1640 medium containing 10% heat-inactivated
fetal bovine serum, 10 mM HEPES buffer, 50 mM 2-mercapto-
ethanol, and antibiotics [penicillin 100 units/ml and streptomycin
100 mg/ml]) in the presence of Hsp60 43-63 peptide, P28-19 55–75
peptide, recombinant P28-19 or E. muris whole cell lysate antigen
(5 mg/ml).. Positive and negative control wells contained conca-
navalin A at a concentration of 5 mg/ml or medium, respectively.
The cells were harvested after 18 hours of in vitro antigen
stimulation (100 microgram per well) followed by 4 hour
incubation with Brefeldin A (BD GolgiPlug, BD Biosciences, San
Diego, CA) and stained with specific antibodies as described
below.
After blocking Fc receptors with anti-Fc II/III receptor mAbs
(BD PharMingen, San Diego, CA) in FACS buffer (Dulbecco’s
PBS without Mg
2+ or Ca
2+ containing 1% fetal calf serum and
0.09% sodium azide) at 4uC for 15 minutes, cells were labeled
with fluorochrome-conjugated mAbs (BD Biosciences Pharmin-
gen, San Diego, CA) specific for mouse CD3 (APC; clone 17A2),
and CD4 (FITC; clone RM4-5), and CD8 (PerCP-Cy 5.5; clone
53–6.7). Later, the cells were fixed, permeabilized and stained
for intracellular IFN-c (PE; clone XMG1.2) using BD Cytofix/
Cytoperm Fixation/Permeabilization kit following the manufac-
turer’s instructions. Flow cytometric data were collected using
FACSCanto (BD Immunocytometry Systems, San Jose, CA).
Live cells were gated based on a vital dye (Near-IR Live/dead
fixable dead cell stain; Invitrogen, Carlsbad, CA), and a total of
200,000 events were collected. Data were analyzed using FCS
Express software (De Novo Software, Los Angeles, CA). Dot
plots were gated on CD3+ T cells and the frequencies and
absolute numbers of antigen-specific IFN-c-producing CD4+ T
cells in the spleens were determined after subtracting the
background staining of unstimulated cells in wells containing
medium only.
Statistical analysis
When indicated, unpaired two-tailed t test was used for
comparison of two groups using GraphPad Prism (GraphPad
Software Inc., La Jolla, CA). Statistical significance was deter-
mined at 95 % (p,0.05).
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